PostPrandial hyPerglycemia and hyperlipidemia have been shown to be risk factors for atherosclerosis [1] [2] [3] . Potential agents to target postprandial hyperglycemia and hyperlipidemia in patients with type 2 diabetes mellitus (T2DM) include α-glucosidase inhibitors (AGIs) and dipeptidyl peptidase (DPP)-4 inhibitors. Miglitol is an AGI that improves postprandial hyperglycemia and hyperlipidemia [4] and reduces postprandial insulin requirements without deteriorating abstract. Postprandial hyperglycemia and/or hyperlipidemia can contribute to development of atherosclerosis in patients with type 2 diabetes mellitus (T2DM). The objective of this study was to compare the effects of miglitol and sitagliptin on postprandial glucose and lipid metabolism in patients with T2DM. Thirty-five patients with T2DM were randomized to 2 groups receiving miglitol (150 mg/day) or sitagliptin (50 mg/day). Serum variables related to glucose and lipid metabolism were measured before and after treatment for 10 weeks and at 0, 60, and 120 min using a cookie-loading test (CLT). After 10 weeks of treatment, miglitol (n = 16) and sitagliptin (n = 18) caused a similarly significant decrease in hemoglobin A 1c (mean: 7.6% to 7.3% versus 8.0% to 7.6%) and a significant increase in fasting insulin levels, with a greater increase observed in the miglitol group than in the sitagliptin group (p=0.03). In addition, a significant decrease in the change in glucose levels after the CLT was observed in both groups, with a greater decrease observed in the miglitol group than in the sitagliptin group (p=0.02). The miglitol group also showed a greater decrease in the change in insulin levels after the CLT than the sitagliptin group (p<0.01). The lipid and lipoprotein levels did not show any significant differences between the groups after the CLT. Our results suggested that miglitol and sitagliptin treatment resulted in similar glycemic control but that a greater decrease in postprandial glucose and insulin levels was observed with miglitol compared with sitagliptin in patients with T2DM.
ipants. The protocol for this study was registered with the UMIN Clinical Trial Registry as UMIN000009502, based on the World Medical Association Declaration of Helsinki guidelines.
Measurements
Body mass index was calculated as weight in kilograms/height in square meters. At baseline and after 10 weeks of treatment, blood samples were collected at the outpatient clinic in the morning after overnight fasting for measurement of the following parameters: HbA 1c , 1,5-anhydro-D-glucitol (1,5-AG), glucose, insulin, glucagon, non-esterified fatty acid (NEFA), total cholesterol, TG, high-density lipoprotein cholesterol, apolipoprotein AI, apolipoprotein AII, apolipoprotein B (ApoB), apolipoprotein CII, apolipoprotein CIII, apolipoprotein E, apolipoprotein B48 (ApoB-48), remnantlike particle cholesterol (RLP-C), aspartate aminotransferase, alanine aminotransferase, and creatinine. A high-performance liquid chromatography (HLC-723 G8; Tosoh, Tokyo, Japan) system was used to measure HbA 1c according to the International Federation of Clinical Chemistry reference standard methods [12] , and HbA 1c values are therefore shown as National Glycohemoglobin Standardization Program equivalent values in this study. 1,5-AG levels were measured using the enzymatic method with the "Lana AG" column-enzyme assay kit (Nippon Kayaku Co. Ltd., Tokyo, Japan) [13] . The homeostasis model assessment of insulin resistance was used to calculate an index from the product of the fasting concentrations of plasma insulin (μIU/ mL) and plasma glucose (mg/dL) divided by 405 [14] . Plasma glucagon levels were measured by the radioimmunoassay method using the Glucagon RIA Kit (Merck Millipore, Merck, Ltd., Billerica, MA, USA). Serum NEFA levels were measured using enzyme reagents (NEFA-SS, Eiken Chemical Co. Ltd., Tokyo, Japan) according to standard techniques. Total cholesterol, TG, high-density lipoprotein cholesterol, aspartate aminotransferase, alanine aminotransferase, and creatinine levels were measured by enzymatic methods using an automatic analyzer (Hitachi Co. Ltd., Tokyo, Japan). Low-density lipoprotein cholesterol levels were calculated by the Friedewald equation because all patients had TG levels less than 400 mg/dL [15] . Serum apolipoprotein AI, apolipoprotein AII, ApoB, apolipoprotein CII, apolipoprotein CIII, and apolipoprotein E levels were determined using turbidimetric immunoassays (Apo A-I Auto N "Daiichi," Apo A-II Auto N the total caloric content was approximately 500 kcal, with 75 g carbohydrate and 18.8 g protein [9] .
Aoki et al. reported the effects of miglitol, sitagliptin, and their combination treatment on plasma glucose, insulin, and incretin levels in healthy men [10] . Each agent reduced postprandial glucose levels within 120 min, and miglitol reduced postprandial insulin levels as well, whereas sitagliptin did not. However, no studies have compared directly postprandial states following treatment with sitagliptin, which enhances insulin levels, and treatment with miglitol, which reduces insulin levels in patients with T2DM. To assess the effects on postprandial hyperglycemia and hyperlipidemia, the aim of the present study was to compare the effects of 10 weeks of treatment with miglitol or sitagliptin on fasting and postprandial glucose and lipid metabolism in patients with T2DM.
subjects and methods

Subjects
Thirty-five patients with T2DM were randomized to 2 groups: one received miglitol (150 mg/day, n=17) and the other received sitagliptin (50 mg/day, n=18) for 10 weeks. Simple randomization was performed in order of clinic visits using a random number table. Based on previous reports that showed a 12-week post-interventional decrease of 0.70% in hemoglobin A 1c (HbA 1c ) with sitagliptin [9] and of 0.16% in HbA 1c with miglitol [11] , the sample size was estimated to be approximately 15 in each group with a significance level (α) of 5% and detection level (1 − β) of 80% (2-tailed). Eligibility criteria were as follows: age > 20 years, the absence of pregnancy, fasting serum triglyceride (TG) levels < 250 mg/dL, HbA 1c < 9.4%, serum creatinine level < 1.0 mg/dL, and no changes in medications during the 3 months before enrollment in the study. We also excluded patients with a history of stroke, cardiovascular events, severe microangiopathy, recent acute illness, inflammatory bowel diseases, past history of ileus, type 1 diabetes mellitus, fasting serum C-peptide level < 0.5 ng/mL and patients who were judged as not appropriate for participation. All subjects were instructed not to change their usual dietary habits and continued their medications, such as lipid-lowering drugs including statins and anti-hypertensive drugs, for the duration of the study. The study protocol was approved by the Jichi Medical University Ethical Committee, and written informed consent was obtained from all partic-ranges for nonparametric variables, and numbers for categorical variables. Nonparametric variables were log-transformed in the analyses. Differences between the 2 groups were examined using the unpaired t-test and the chi-square test. Differences before and after treatment in each group were examined using paired t-tests, and differences before and after treatment between the 2 groups were examined using a 2-way (group and time) analysis of variance (ANOVA). With regard to the effects of the CLT on variables, changes of respective variables within each group were examined using repeated-measures ANOVA (followed by posthoc multi-comparison Bonferroni tests), and changes between the 2 groups were examined using 2-way (group and timing) ANOVA. Correlations between changes in variables were examined using Pearson tests. Changes in respective variables after the CLT were also assessed by the area under the curve (AUC), calculated using the trapezoidal method [20] . Statistical significance was set at a p-value of less than 0.05. All analyses were performed using the SPSS II software package (IBM Corporation, Armonk, NY, USA).
results
Patients
After randomization, one patient in the miglitol group dropped out of the study because of abdominal distention. The demographic characteristics of the patients were similar between the 2 treatment groups ( Table 1) , and variables related to glucose and lipid metabolism were similar between the 2 groups. However, the sitagliptin group had significantly higher levels of fasting insulin and homeostasis model assessment of insulin resistance than the miglitol group (Table 2) .
Parameters related to glucose metabolism
The changes from baseline in HbA 1c , as the pri-"Daiichi," Apo B Auto N "Daiichi," Apo C-II Auto N "Daiichi," Apo C-III Auto N "Daiichi," and Apo E Auto N "Daiichi"; Sekisui Medical Co. Ltd., Tokyo, Japan). ApoB-48 levels were measured by enzyme immunoassay (Lumipulse apo B48; Fujirebio, Inc., Tokyo, Japan) according to the method described by Uchida et al [16] . RLP-C levels were measured using an immunoseparation method (RLP-C Jimro II Kit; Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan) [17] .
Cookie-loading test
The cookie-loading test (CLT) was performed after an overnight fast using previously described methods [18] at baseline and 10 weeks after the start of each treatment. Subjects were instructed to refrain from smoking and drinking coffee or alcoholic beverages beginning the night before the study. The cookie consisted of 75 g carbohydrate, 28.5 g butter, and 8 g protein for 592 kcal (Saraya Co. Ltd., Osaka, Japan). Subjects were encouraged to ingest the cookie with water within 15 min. Time measurement was started when half of the cookie had been ingested. Sitagliptin and 100 mL water were given 30 min before the CLT as previously reported [9] , whereas miglitol and 100 mL water were given immediately before the CLT [19] . Blood samples were obtained during the fasting state before cookie ingestion and at 60 min and 120 min after the cookie load. Plasma glucose, insulin, glucagon, TG, Apo-B, RLP-C, and NEFA levels were determined at each time point.
Data analysis
The primary outcomes were change from baseline in HbA 1c at 10 week between the 2 groups. The secondary outcomes were parameters related to glucose metabolism (except HbA 1c ) and lipid metabolism. The data are presented as mean ± standard deviation (SD) for parametric variables, medians with interquartile Data are presented as the number, percentage, mean ± SD, or median (interquartile range). p<0.05 as a comparison between the miglitol and sitagliptin groups.
decreased glucose levels during the CLT were significantly greater in the miglitol group than in the sitagliptin group (p=0.02). The changes in insulin and glucagon levels were different between the miglitol and sitagliptin groups. After 10 weeks of treatment, plasma insulin levels were significantly increased in both groups after the CLT. However, changes in insulin levels were significantly increased in the sitagliptin group but were suppressed in the miglitol group (p<0.01). Plasma glucagon levels were significantly increased in the miglitol group after the CLT. In contrast, plasma glucagon levels remained essentially stable in the sitagliptin group after the CLT. The AUCs for glucose, insulin, and glucagon levels during the CLT before and after treatment are shown mary endpoint, at 10 week were similar between the 2 groups ( Table 2 ). After 10 weeks of treatment, HbA 1c levels were significantly decreased in both groups, whereas 1,5-AG levels were significantly increased in both groups. Treatment with miglitol significantly increased changes in fasting insulin levels compared with treatment with sitagliptin at 10 weeks (p=0.03).
Plasma glucose, insulin, and glucagon levels during the CLT before and after treatment are shown in Fig. 1 . Plasma glucose, insulin, and glucagon levels were significantly increased during the CLT before and after 10 weeks for both treatments. After 10 weeks of treatment, both the miglitol and sitagliptin groups exhibited a significant reduction in glucose levels before and at 60 and 120 min after the CLT. Mean changes in , hemoglobin A 1c ; 1,5-AG, 1,5-anhydro-D-glucitol; HOMA-IR, homeostasis model assessment of insulin resistance; NEFA, nonesterified fatty acid; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RLP-C, remnant-like particle cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase. Data are presented as the mean ± SD or median (interquartile range). *p 1 <0.05, comparison of respective data between baseline and after 10 weeks of treatment with miglitol or sitagliptin; *p 2 <0.05, comparison of baseline data between the miglitol and sitagliptin groups; *p 3 <0.05, comparison of changes in respective data between the miglitol and sitagliptin groups; When the patient in the miglitol group who dropped out was considered in the analyses, the results (p-values) did not change. analyses of changes in glucose levels after CLT, the results did not change (data not shown).
Parameters related to lipid metabolism
Plasma TG, ApoB-48, and RLP-C levels were significantly increased and NEFA levels were significantly decreased during the CLT before and after 10 weeks of treatment for both groups (Table 4 ). However, TG, ApoB-48, RLP-C, and NEFA levels did not significantly change in both groups at 10 weeks after the CLT as compared with week 0.
The miglitol group exhibited a significant reduction in the AUCs of TG, ApoB-48, and RLP-C after 10 weeks of treatment (Table 3 ). On the other hand, the sitagliptin group exhibited a significant reduction only in the AUC of ApoB-48 after 10 weeks of treatment. The AUCs for NEFA were similar in both groups before and after 10 weeks for each treatment.
in Table 3 . Before treatment, the AUCs for glucose and insulin levels were similar between the 2 groups. After 10 weeks of treatment, the AUC for glucose levels was significantly decreased in both groups (p<0.01 in both groups). In particular, the AUC for glucose levels decreased significantly from 60 to 120 min in the miglitol group but not in the sitagliptin group (p=0.02). After 10 weeks of treatment, the AUC for insulin levels was significantly decreased in the miglitol group. On the other hand, the AUC for insulin levels tended to increase in the sitagliptin group. Although the AUC for glucagon levels was increased in the miglitol group, especially from 60 to 120 min, the AUC for glucagon levels was significantly decreased in the sitagliptin group. In addition, although the patient in the miglitol group who dropped out was considered in these analyses, the results did not change significantly. When an at-baseline insulin adjustment was performed in the RLP, remnant-like particle cholesterol; NEFA, non-esterified fatty acid. Data are presented as the mean ± SD or median (interquartile range). p 1 , comparison of respective data between baseline and after 10 weeks of treatment with miglitol or sitagliptin; p 2 , comparison of changes in respective data between the miglitol and sitagliptin groups. † When baseline insulin-adjusted analysis was performed, the results (p-values) did not change.
intestine; therefore, a relatively higher amount of carbohydrates was absorbed in the lower portion of the small intestine [5, 10, 21, 22] . The tendency for decreased insulin levels may explain the increased glucagon levels with miglitol treatment [23] . In contrast, sitagliptin has been shown to enhance the activity of GLP-1 and GIP by inhibiting DPP-4 enzymatic activity; therefore, sitagliptin increases serum insulin and decreases serum glucagon levels in patients with T2DM [6, 24] . A meal tolerance test such as the CLT has a greater effect on GIP secretion than GLP-1 secretion, and the GIP level peaked at 30 min in Japanese patients with T2DM [25] . GIP contributes more to secretion of insulin than does GLP-1 [26] on the basis of the baseline HbA 1c in this study. Thus, although we did not measure GLP-1 and GIP levels as well as glucose and lipid parameters at 30 min during the CLT in this study, we expect that this difference can be partly explained by the fact that glucagon, in addition to GIP rather than GLP-1, is regulated by insulin levels [27] . In our study, mean values of changing postprandial hyperlipidemia exhibited similar reductions in discussion Although both miglitol and sitagliptin treatment similarly reduced glucose levels after 10 weeks, miglitol caused a greater reduction in postprandial hyperglycemia through a mechanism involving the regulation of insulin levels that was contradictory to that of the sitagliptin mechanism. This head-to-head prospective comparative study between miglitol and sitagliptin treatment for 10 weeks revealed different changes in insulin and glucagon levels during the CLT.
Elevation of postprandial glucose levels was suppressed significantly by both miglitol and sitagliptin in this study. However, postprandial insulin and glucagon levels were different between the 2 groups. Lower plasma insulin levels with higher glucagon levels were seen in the miglitol group, whereas a moderate increase in insulin levels with lower glucagon levels was seen in the sitagliptin group. Miglitol enhances glucagonlike peptide-1 (GLP-1) secretion and reduces glucosedependent insulinotropic polypeptide (GIP) secretion through absorption in the upper portion of the small This study has a limitation related to the interpretation of data that warrants mention. First, the sample size was small; thus, larger studies are required for a definitive conclusion. Second, although this study has the advantage of being a prospective, randomized, controlled study, a double-blind design was not applied. Changes in fasting insulin levels exhibited a greater increase with miglitol in this study. We cannot exactly explain the reason for this; however, it is possible that concomitant use of sulfonylurea agents was higher in this study than in previous studies, in which case miglitol improved insulin resistance [5, 37] . In addition, fasting insulin levels at baseline were higher in the miglitol group than in the sitagliptin group. Because this difference may influence the results, a randomized study that includes fasting insulin levels at baseline is necessary. Third, the interventional period may have been too short; therefore, a longer follow-up study is required. Finally, it remains to be elucidated whether the highest dosage of miglitol (75 mg 3 times a day) or sitagliptin (100 mg once a day) would have a stronger effect on modulating postprandial glucose and lipid levels than the dose used in this study. Furthermore, to achieve the effects of miglitol treatment seen in this study, adherence to treatment is very important because of the need to take this medication 3 times a day and avoid many side effects, such as flatulence, abdominal distention, and borborygmus.
In conclusion, the results of the present study suggest that miglitol may have more beneficial effects on postprandial glucose levels than sitagliptin by means of suppressed increasing insulin levels after the CLT, although sitagliptin improved postprandial glucose levels by increasing insulin levels and suppressing glucagon levels. Furthermore, both miglitol and sitagliptin may have beneficial effects on postprandial lipoprotein metabolism in patients with T2DM. acknowledgments This work was supported by an unrestricted research grant from the Joint Research Association for Japanese Diabetes.
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both treatment conditions. Although the mechanism of this metabolic phenotype has not been clarified, this observation may have resulted from delays in gastric emptying without adverse effects on postprandial lipid levels caused by reduced postprandial insulin secretion induced by miglitol [5] . Increased GLP-1 levels induced by miglitol after the CLT, leading to deceleration of gastric emptying, likely contributed to suppressed increases in postprandial exogenous lipid levels in the early phase [5, 10, 23, 28] . In contrast, there are several mechanisms through which sitagliptin could have improved postprandial lipid levels. Tremblay et al. reported that sitagliptin reduced postprandial TG-rich lipoproteins of intestinal and hepatic origin by increasing incretin hormone levels, reducing circulating plasma NEFA levels, and improving insulin sensitivity and β-cell function [7] . Vildagliptin and alogliptin also reduced postprandial intestinal TG-rich lipoprotein particles in T2DM due to the effects of either GLP-1 or GIP in the gut [29, 30] . Although we did not measure GLP-1 and GIP levels, the influence of sitagliptin on postprandial lipid levels could reflect incretin-mediated changes in pancreatic hormone secretion, the improved metabolic state, and reduced insulin resistance secondary to improved islet function, incretin-mediated slowing of gastric emptying, or direct effects of GLP-1 and/or GIP on lipoprotein metabolism. We did not observe lowered NEFA levels or improvement of insulin resistance after treatment with sitagliptin. Because sitagliptin treatment demonstrated a significant reduction in ApoB-48 levels, but not ApoB levels, our results also suggested that sitagliptin might affect the intestinal decrease of lipoprotein rather than hepatic lipoprotein production.
In this study, miglitol demonstrated a significantly greater suppression of both postprandial glucose and insulin levels than did sitagliptin. Meta-analysis has shown that both acarbose, one of the AGIs [31] , and DPP-4 inhibitors [32] can reduce cardiovascular events in patients with T2DM. In addition, postprandial glucose levels peaked from 60 to 120 min with a mundane meal in patients with T2DM [33] and were a risk factor for a cardiovascular event [34, 35, 36] . Miglitol treatment significantly suppressed the AUC for glucose levels not from 0 to 60 min but from 60 to 120 min, in contrast to that observed with sitagliptin in this study. Therefore, miglitol may have longer effectiveness for reduction of cardiovascular events than sitagliptin from
